

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 06 February 2024

FOI Ref No: 23516

Requested Information

1) How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease
- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepiti) – any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) – any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

2) How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

3) Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Response

1) How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease 0

- Erenumab (Aimovig) - any disease **44**
- Eptinezumab (Vypti) – any disease **0**
- Fremanezumab (Ajovy) - any disease **18**
- Galcanezumab (Emgality) - any disease **10**
- Rimegepant (Vydura) – any disease **0**
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY **we do not record indication so would not know what this drug was given to treat. For any disease: 370**

2) How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

We do not record indication so would not be able to provide figures of what a drug was given to treat.

Our clinical coding team have confirmed:

‘We aren’t able to classify them as; chronic migraine (15+ headache days per month) or episodic migraine (4-15 headache days per month) through our clinical coding.’ So we could not split them either.

3) Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

The electronic prescribing team are unable to answer this clinical question.

Attachment(s)

Date Response sent: